Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nanomedicine : nanotechnology, biology, and medicine

• Publication date

  2011-10-01

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.1016/j.nano.2011.03.008PMID 21477665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization.

  2011cited by this paper
• Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide.

  2011cited by this paper
• Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease.

  2010cited by this paper
• New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide.

  2010cited by this paper
• Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

  2010cited by this paper
• Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.

  2010cited by this paper
• Size-dependent neurotoxicity of beta-amyloid oligomers.

  2010cited by this paper
• Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

  2010cited by this paper
• Localized Surface Plasmon Resonance Biosensing with Large Area of Gold Nanoholes Fabricated by Nanosphere Lithography

  2010cited by this paper
• ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model.

  2010cited by this paper
• Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide.

  2010cited by this paper
• Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle

  2010cited by this paper
• In vivo labelling of hippocampal β‐amyloid in triple‐transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles

  2010cited by this paper
• Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering.

  2010cited by this paper
• Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation.

  2010cited by this paper
• Advances in the treatment of neurodegenerative disorders employing nanotechnology

  2010cited by this paper
• Polycation cytotoxicity: a delicate matter for nucleic acid therapy-focus on polyethylenimine

  2010cited by this paper
• Randomization of amyloid-β-peptide(1-42) conformation by sulfonated and sulfated nanoparticles reduces aggregation and cytotoxicity.

  2010cited by this paper
• Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system

  2010cited by this paper
• Targeting the brain--surmounting or bypassing the blood-brain barrier.

  2010cited by this paper
• Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.

  2010cited by this paper
• Synthesis and characterization of poly(ethylene glycol)-glutathione conjugate self-assembled nanoparticles for antioxidant delivery.

  2009cited by this paper
• Cellular copper import by nanocarrier systems, intracellular availability, and effects on amyloid beta peptide secretion.

  2009cited by this paper
• Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles

  2009cited by this paper
• Nanogels as pharmaceutical carriers: finite networks of infinite capabilities.

  2009cited by this paper
• Effect of maghemite nanoparticles on insulin amyloid fibril formation: selective labeling, kinetics, and fibril removal by a magnetic field.

  2009cited by this paper
• Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle.

  2009cited by this paper
• Protective actions of sex steroid hormones in Alzheimer's disease.

  2009cited by this paper
• The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity.

  2009cited by this paper
• Copper nanoparticles-modified carbon paste transducer as a biosensor for determination of acetylcholine.

  2009cited by this paper
• Zinc in the physiology and pathology of the CNS

  2009cited by this paper
• Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field.

  2009cited by this paper
• A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.

  2009cited by this paper
• Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study.

  2009cited by this paper
• Ultra-sensitive immunosensor for beta-amyloid (1-42) using scanning tunneling microscopy-based electrical detection.

  2009cited by this paper
• A Condensation-Ordering Mechanism in Nanoparticle-Catalyzed Peptide Aggregation

  2009cited by this paper
• Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

  2009cited by this paper
• Real-Time Imaging and Quantification of Amyloid-β Peptide Aggregates by Novel Quantum-Dot Nanoprobes

  2009cited by this paper
• Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT).

  2009cited by this paper
• Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

  2009cited by this paper
• Structure–neurotoxicity relationships of amyloid β-protein oligomers

  2009cited by this paper
• Amyloid β-Protein Assembly and Alzheimer Disease*

  2009cited by this paper
• Signal enhancement of surface plasmon resonance based immunosensor using gold nanoparticle-antibody complex for beta-amyloid (1-40) detection.

  2009cited by this paper
• Nanoparticles can cause DNA damage across a cellular barrier.

  2009cited by this paper
• Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier.

  2008cited by this paper
• Amyloid-beta detection with saccharide immobilized gold nanoparticle on carbon electrode.

  2008cited by this paper
• Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid beta self-assembly.

  2008cited by this paper
• Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.

  2008cited by this paper
• Superoxide Dismutase-Loaded PLGA Nanoparticles Protect Cultured Human Neurons Under Oxidative Stress

  2008cited by this paper
• Hormonal treatment, mild cognitive impairment and Alzheimer's disease

  2008cited by this paper
• Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover.

  2008cited by this paper
• Nanotechnology Solutions for Alzheimer's Disease: Advances in Research Tools, Diagnostic Methods and Therapeutic Agents

  2008cited by this paper
• Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.

  2008cited by this paper
• Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42.

  2008cited by this paper
• Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting

  2008cited by this paper
• Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  2008cited by this paper
• Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide.

  2008cited by this paper
• Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.

  2008cited by this paper
• Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles.

  2008cited by this paper
• Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.

  2007cited by this paper
• Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells

  2007cited by this paper
• Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.

  2007cited by this paper
• Nephroprotective and hepatoprotective effects of curcuminoids.

  2007cited by this paper
• Gold nanoparticles for selective and remote heating of β-amyloid protein aggregates

  2007cited by this paper
• Comparison of drug sensitivity using acetylcholinesterase biosensor based on nanoparticles–chitosan sol–gel composite

  2007cited by this paper
• Pharmacokinetics and pharmacodynamics of curcumin.

  2007cited by this paper
• Iron: The Redox-active Center of Oxidative Stress in Alzheimer Disease

  2007cited by this paper
• Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation

  2007cited by this paper
• Nonviral delivery of synthetic siRNAs in vivo.

  2007cited by this paper
• Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide*

  2007cited by this paper
• Bioavailability of curcumin: problems and promises.

  2007cited by this paper
• Immunological properties of engineered nanomaterials

  2007cited by this paper
• Attenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment.

  2007cited by this paper
• Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides

  2006cited by this paper
• Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases.

  2006cited by this paper
• 100 Years and Counting: Prospects for Defeating Alzheimer's Disease

  2006cited by this paper
• Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production

  2006cited by this paper
• Nanoparticle-mediated local and remote manipulation of protein aggregation.

  2006cited by this paper
• PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro.

  2006cited by this paper
• Inhibition of Amyloid β Peptide Fibril Formation by Hydrogel Nanoparticles

  2006cited by this paper
• Localized surface plasmon resonance biosensors.

  2006cited by this paper
• Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers.

  2006cited by this paper
• Molecular interactions of dendrimers with amyloid peptides: pH dependence.

  2006cited by this paper
• Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice

  2006cited by this paper
• Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease.

  2005cited by this paper
• A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy.

  2005cited by this paper
• Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.

  2005cited by this paper
• A potential role of the curry spice curcumin in Alzheimer's disease.

  2005cited by this paper
• Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

  2005cited by this paper
• Low and high molecular weight poly(l‐lysine)s/poly(l‐lysine)–DNA complexes initiate mitochondrial‐mediated apoptosis differently

  2005cited by this paper
• Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes.

  2005cited by this paper
• C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.

  2005cited by this paper
• Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor.

  2005cited by this paper
• Nanomedicine: current status and future prospects

  2005cited by this paper
• Nanoscience enables ultrasensitive detection of Alzheimer's biomarker.

  2005cited by this paper
• Solid lipid nanoparticles for parenteral drug delivery.

  2004cited by this paper
• Interaction between amyloid β‐protein aggregates and membranes

  2004cited by this paper
• Immunotherapy for Alzheimer's disease

  2004cited by this paper

• Advancing cancer therapy: Nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin

  2025cites this paper
• Hydrogel Based Nanocomposition System: Characterization and Application for Drug Delivery System

  2025cites this paper
• Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer’s Disease

  2025cites this paper
• Polymeric-Based Theranostic Nanocarriers of Neuroprotective Drugs: Development, Imaging, and Bioanalysis

  2025cites this paper
• Nanozymes: Innovative Therapeutics in the Battle Against Neurodegenerative Diseases

  2025cites this paper
• Therapeutic and clinical potential of thiolutin microneedles on Alzheimer's disease mitigation.

  2025cites this paper
• Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.

  2025cites this paper
• Detection of an oxidative stress metabolite associated with neurodegenerative diseases: effect of heteroatom doped antioxidant carbon dots

  2025cites this paper
• Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer’s disease

  2025influential citation
• Evaluating Nanotoxicity: Integrating Invitro and Invivo Models for Risk Assessment

  2025cites this paper
• Peroxynitrite-induced structural alterations render human fibrinogen more immunogenic: A possible mechanism of auto-immune response that acts as a proatherogenic marker.

  2025cites this paper
• New lanthanum (III) complexes containing azaphosphor β-diketon and diimine ligands: Synthesis, crystallography, morphology properties, DNA binding, DNA cleavage, and DFT calculation.

  2024cites this paper
• How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

  2024cites this paper
• Nanoparticle delivery for central nervous system diseases and its clinical application

  2024cites this paper
• Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Aβ1-42 Neurotoxicity in In-Vivo Model

  2024cites this paper
• Metal–Organic Frameworks as Sensors for Human Amyloid Diseases

  2023cites this paper
• Associations of sugar-sweetened, artificially sweetened, and naturally sweet juices with Alzheimer’s disease: a prospective cohort study

  2023cites this paper
• Metal organic framework modulated nanozymes tailored with their biomedical approaches

  2023cites this paper
• Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

  2023cites this paper
• Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer’s Disease Treatment

  2023cites this paper
• Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression

  2023cites this paper
• Strategies for enhanced bioavailability of oxime reactivators in the central nervous system

  2023cites this paper
• Vitamin E modified polyamidoamine dendrimer for piperine delivery to alleviate Aβ1–42 induced neurotoxicity in Balb/c mice model

  2023cites this paper
• A Neurospheroid‐Based Microrobot for Targeted Neural Connections in a Hippocampal Slice

  2023cites this paper
• Research gap and trend in neurological therapy related to nanotechnology based on bibliometric analysis

  2023cites this paper
• Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease.

  2023cites this paper
• Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation

  2022cites this paper
• Fabrication of TPGS-Grafted Polyamidoamine Dendrimer for Enhanced Piperine Brain Delivery and Pharmacokinetics

  2022cites this paper
• Future of Alzheimer’s Disease: Nanotechnology-Based Diagnostics and Therapeutic Approach

  2022cites this paper
• Nanomedicine-based immunotherapy for Alzheimer's Disease.

  2022cites this paper
• Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives

  2022cites this paper
• Ameliorative Effects by Hexagonal Boron Nitride Nanoparticles against Beta Amyloid Induced Neurotoxicity

  2022cites this paper
• Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease.

  2022cites this paper
• Biomedical Applications of Metal−Organic Frameworks for Disease Diagnosis and Drug Delivery: A Review

  2022cites this paper
• Therapeutic nanotechnologies for Alzheimer's disease: a critical analysis of recent trends and findings.

  2022cites this paper
• Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery

  2022cites this paper
• HexA-Enzyme Coated Polymer Nanoparticles for the Development of a Drug-Delivery System in the Treatment of Sandhoff Lysosomal Storage Disease

  2022cites this paper
• New TEMPO–Appended 2,2′-Bipyridine-Based Eu(III), Tb(III), Gd(III) and Sm(III) Complexes: Synthesis, Photophysical Studies and Testing Photoluminescence-Based Bioimaging Abilities

  2022cites this paper
• Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients.

  2022cites this paper
• Design and performance simulation of a highly sensitive nano-biosensor based on a realistic array of plasmonic synthesized nanostructures

  2022cites this paper
• Insights for Alzheimer's disease pharmacotherapy and current clinical trials.

  2022cites this paper
• Volumetric Feature-Based Alzheimer’s Disease Diagnosis From sMRI Data Using a Convolutional Neural Network and a Deep Neural Network

  2021cites this paper
• Therapeutic nanostructures and nanotoxicity

  2021cites this paper
• Nanomedicines for Brain Drug Delivery

  2021cites this paper
• Physical and chemical properties of carbon nanotubes in view of mechanistic neuroscience investigations. Some outlook from condensed matter, materials science and physical chemistry.

  2021cites this paper
• PEGylated Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Ameliorate Learning and Memory Deficit in a Rat Model of Alzheimer's Disease: Potential Participation of STIMs.

  2021cites this paper
• Alzheimer's Disease: Pathogenesis and Therapeutic interventions.

  2021cites this paper
• Nanodelivery systems for Alzheimer’s disease: Prospects of natural therapeutic agents

  2021influential citation
• Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer’s disease diagnosis and progression monitoring

  2021cites this paper
• Nanomedicine and drug delivery

  2021cites this paper
• The Potential Benefits of Nanotechnology in Treating Alzheimer's Disease

  2021influential citation
• PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

  2021cites this paper
• Biogenic synthesis of gold and silver nanoparticles used in environmental applications: A review

  2021cites this paper
• Photothermal and Photodynamic Therapies via NIR-Activated Nanoagents in Combating Alzheimer's Disease.

  2021cites this paper
• Kinetics of nanoparticle uptake into and distribution in human cells

  2021cites this paper
• Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

  2021cites this paper
• Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury.

  2021cites this paper
• Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

  2021cites this paper
• Nanocarriers for Alzheimer’s disease: Research and patent update

  2021cites this paper
• Advances Toward the Development of New Therapeutic Strategies Targeting Acetylcholinesterase and Its Remediation Processes

  2021cites this paper
• Melatonin: Regulation of Biomolecular Condensates in Neurodegenerative Disorders

  2021cites this paper
• Magnetic Nanoparticles as Delivery Systems to Penetrate the Blood-Brain Barrier

  2020cites this paper
• Kinetics of Drug Release via Nicardipine Hydrochloride‐loaded Carboxymethyl Cellulose/Poly(D,L‐lactic‐co‐glycolic acid) Nanocarriers Using a Contemporary Emulsion Process

  2020cites this paper
• Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's.

  2020cites this paper
• Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.

  2020cites this paper
• Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

  2020cites this paper
• Advances of Nanoparticles for Leukemia Treatment.

  2020cites this paper
• Bioactive properties of chitosan stabilized magnetic nanoparticles – Focus on hyperthermic and anti-amyloid activities

  2020cites this paper
• Multifunctional nano-enabled delivery systems in Alzheimer's disease management.

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• Fluorescent Dopamine-tryptophan nanocomposites as dual imaging and anti-aggregation agents: New generation of amyloid theranostics with trimeric effects.

  2020cites this paper
• Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

  2020cites this paper
• Chrysin loaded lipid-core nanocapsules ameliorates neurobehavioral alterations induced by β-amyloid1-42 in aged female mice.

  2020cites this paper
• The Impact of Ag Nanoparticles and CdTe Quantum Dots on Expression and Function of Receptors Involved in Amyloid-β Uptake by BV-2 Microglial Cells

  2020cites this paper
• Fluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?

  2020cites this paper
• Nanotoxicity: a challenge for future medicine

  2020cites this paper
• Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

  2020cites this paper
• Selected nanotechnologies and nanostructures for drug delivery, nanomedicine and cure

  2020cites this paper
• Chitosan-based nanomedicine for brain delivery: Where are we heading?

  2020cites this paper
• Nanogold neuroprotection in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction.

  2020cites this paper
• ADVANCEMENT OF NANOTECHNOLOGY IN THE FIELD OF MEDICINE

  2020cites this paper
• Evaluation of the potential of nanoparticles containing active substances in selected chronic diseases.

  2020cites this paper
• Nanotechnology-based devices in the treatment for Alzheimer’s disease

  2020cites this paper
• Nano‐ and micro‐structure tin (IV) complexes bearing 4‐pyridinecarbacylamidophosphate: Sonochemical synthesis, crystal structure, anti‐cholinesterase activity, and docking studies

  2020cites this paper
• Recent advancements in polyethyleneimine-based materials and their biomedical, biotechnology, and biomaterial applications.

  2020cites this paper
• Real-time PCR for direct aptamer quantification on functionalized graphene surfaces

  2019cites this paper
• Hydrogel Nanocomposite Systems

  2019cites this paper
• Role of nanostructures in improvising oral medicine

  2019cites this paper
• Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders.

  2019cites this paper
• Scientific applications and prospects of nanomaterials: A multidisciplinary review

  2019cites this paper
• Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy.

  2019cites this paper
• Nanoneuromedicine for management of neurodegenerative disorder

  2019cites this paper
• Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems.

  2019cites this paper
• Diminished amyloid-β uptake by mouse microglia upon treatment with quantum dots, silver or cerium oxide nanoparticles: Nanoparticles and amyloid-β uptake by microglia

  2019cites this paper
• Iron oxide nanoparticles for therapeutic applications.

  2019cites this paper
• Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities

  2019cites this paper
• Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery.

  2019cites this paper
• Field-variable magnetic domain characterization of individual 10 nm Fe3O4 nanoparticles

  2019cites this paper
• Nano-carriers for drug routeing – towards a new era

  2019cites this paper
• A novel kit for early diagnosis of Alzheimer’s disease using a fluorescent nanoparticle imaging

  2019cites this paper